Life After Big Pharma: Why Going Small Was A Good Choice

By Bill Breitenbach

After 25 years of working my way through major corporations in biopharma, I’ve made the jump from a massive organization to a small — or perhaps better said, a tiny — organization for an opportunity to launch a product that takes care of a very small population of children with congenital heart disease.

My previous organization had 40,000+ employees. At Mezzion Pharmaceuticals, I was employee No. 5 in the U.S., and we’re on our way to doubling that number.